A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo
added to donepezil, in patients with mild to moderate Alzheimer's disease. Following a
screening period, patients will be randomized to one of 4 treatments (placebo, or RO5313534
1mg, 5mg or 15mg po daily) with background therapy of donepezil (5mg or 10mg).The anticipated
time on study treatment is 6 months, and the target sample size is 100-500 individuals.